Campari (CPR IM) Q3 2026 (EUR): Revenue 777mln (exp. 769mln); confirm FY26 guidance of circa +3% organic topline growth

Campari (CPR IM) Q3 2026 (EUR): Revenue 777mln (exp. 769mln); confirm FY26 guidance of circa +3% organic topline growth.

A modest revenue beat alongside reaffirmed guidance is the classic 'in-line-plus' print: for consumer staples names, guidance confirmation has historically mattered more to the shares than small quarterly beats, since the question through recent cycles has been whether spirits makers can hold organic topline targets amid soft demand in key markets and destocking in the US. Campari's track record here is relevant: the group has repeatedly reiterated full-year targets through the year and the pattern has been that revisions, not beats, move the stock, with aperitif seasonality skewing the weight of evidence toward the second half. The distinction worth drawing is between the organic topline line, which management controls the narrative on, and the margin and FX lines, where emerging market exposure and input costs have tended to be where estimates actually drift. What follows is the margin detail and any commentary on US distributor inventory and pricing, which in past print cycles have been the items that separate a hold from a de-rating for the spirits peer set. As a small beat with confirmed guidance, the read is continuation rather than new information.